Quinazoline Salt Crystal Forms for EGFRVIII Inhibition and BBB Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing EGFR inhibitors are ineffective against EGFRVIII mutations and struggle to cross the blood-brain barrier, limiting their efficacy in treating gliomas, and the free base form of quinazoline derivatives is not suitable for pharmaceutical processing.
Innovation Solution
Development of novel quinazoline derivative salt crystal forms with high chiral purity, specifically hydrochloride forms A to I, and other salt forms like fumarate, succinate, and benzenesulfonate, which exhibit specific XRPD patterns and enhance pharmaceutical processing, providing biological activity against EGFRVIII mutations and the ability to cross the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EGFR inhibitors are used, then they can inhibit wild-type EGFR, but they are ineffective against EGFRVIII mutations and cannot cross the blood-brain barrier
Solution Approach 1:
The patent modifies the chemical parameters of EGFR inhibitors by introducing specific structural features: a difluoromethylpiperidine moiety at position 6 and an ethynyl group at position 2 of the phenyl ring. These parameter changes enable the compound to effectively inhibit EGFRVIII mutations while maintaining the ability to cross the blood-brain barrier, resolving the contradiction between mutation-specific efficacy and blood-brain barrier penetration.
2Reliability
If free base form of quinazoline derivatives is used, then it has biological activity, but it is not suitable for pharmaceutical processing
Solution Approach 1:
The patent changes the physical-chemical parameters of the quinazoline derivative by converting the free base form into salt crystal forms through reaction with acids such as hydrochloric acid, fumaric acid, succinic acid, and benzenesulfonic acid. This parameter change improves pharmaceutical processing suitability including stability, solubility, and manufacturability while preserving the biological activity against EGFRVIII mutations.
Solution Approach 2:
The patent utilizes phase transition from the free base form to salt crystal forms. The free base is converted into crystalline salt forms through acid-base reactions, which improves handling, storage, and pharmaceutical processing properties. The crystal forms exhibit specific XRPD patterns that confirm their distinct phase structure, maintaining biological activity while enabling practical pharmaceutical manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel quinazoline derivative salt crystal forms effectively inhibit EGFRVIII mutations and penetrate the blood-brain barrier, offering improved therapeutic potential for gliomas and other cancers.
Implementation Method 1
Development of novel quinazoline derivative salt crystal forms with high chiral purity, specifically hydrochloride forms A to I, and other salt forms like fumarate, succinate, and benzenesulfonate, which exhibit specific XRPD patterns
Data Source
AI summary
A quinazoline derivative (represented by the formula (I)) salt's crystal form, a preparation method and application are provided; specifically, the hydrochloride crystal form A, B, C, D, F, H, I, Sulphate crystal form A, Maleate crystal form A, Succinate crystal form A, Adipate crystal form A, Glycolate crystal form A, Malate crystal form A, Fumarate Salt crystal form A, besylate crystal form A, B, C, benzoate crystal form A, hippurate crystal form A and oxalate crystal form A of the quinazoline derivative represented by formula (I). The salt crystal form provided by the present invention has good stability, which can be used in the treatment of non-small cell lung cancer brain metastasis, meningeal metastasis, primary brain cancer or glioma, etc., and has good bioavailability, which is of great significance for further research on the efficacy of such solid drugs.